We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+83.13%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$567M
AUM Growth
+$233M
Cap. Flow
+$110M
Cap. Flow %
19.49%
Top 10 Hldgs %
79.55%
Holding
26
New
5
Increased
7
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$27M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$25.2M
3
VTYX
Ventyx Biosciences
VTYX
+$23.3M
4
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$18.8M
5
KALV
KalVista Pharmaceuticals
KALV
+$18.2M

Top Sells

Rank Stock Value
1
ALLK
Allakos
ALLK
+$10.1M
2
AKUS
Akouos Inc
AKUS
+$9.13M
3
TNGX icon
Tango Therapeutics
TNGX
+$4.24M
4
VRDN icon
Viridian Therapeutics
VRDN
+$4.16M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKUS
26
DELISTED
Akouos Inc
AKUS
– –
-1,350,006
Closed -$9.13M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return
TH
TCTC Holdings Dallas, Texas $3.51B AUM 30.71% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

TCG Crossover Management's Q4 2022 Portfolio in Review

As of Q4 2022, TCG Crossover Management held 26 positions worth $567M, up 70% from $333M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

TCG Crossover Management deployed $110M of net new capital in Q4 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was Ventyx Biosciences: 787,231 shares worth $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $4.16M trimmed.

  • TCG Crossover Management's largest Q4 2022 buy was Ventyx Biosciences: 787,231 shares worth $25.8M.
  • TCG Crossover Management added most to IVERIC bio, Inc. Common Stock in Q4 2022, an estimated $27M increase.
  • TCG Crossover Management's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $4.16M.
  • TCG Crossover Management fully exited Allakos in Q4 2022, selling an estimated $10.1M.
  • TCG Crossover Management's ten largest holdings make up 80% of its $567M portfolio in Q4 2022.
  • TCG Crossover Management opened 5 new positions and closed 5 in Q4 2022.
  • TCG Crossover Management's portfolio value rose 70% quarter-over-quarter to $567M.

Based on TCG Crossover Management's 13F filing for Q4 2022, filed 14 Feb 2023.